C4X Discovery Holdings PLC Board Change (8990S)
November 19 2021 - 2:00AM
UK Regulatory
TIDMC4XD
RNS Number : 8990S
C4X Discovery Holdings PLC
19 November 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Board Change
19 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces that Craig Fox,
Chief Scientific Officer ("CSO"), has informed the Company of his
intention to step down from his role and the Board, after six years
of service, to pursue a new opportunity. Craig is expected to leave
the Company by 31 March 2022 and a search for a new CSO has
commenced. A further announcement will be made in due course.
Clive Dix, Chief Executive Officer of C4X Discovery, commented:
"Craig has been an important part of the C4XD team and his
scientific know-how and expertise has contributed to a plethora of
exciting scientific discoveries that have led to the signing of
major outlicensing agreements. On behalf of the Board, I would like
to express my sincere gratitude to Craig for his dedication and
valuable contribution to the Company during his six years of
service. We wish Craig continued success in all his future
endeavours."
Craig Fox commented: "I have thoroughly enjoyed my time at C4XD,
and it has been a privilege to work with its fantastic people and
to see the Company transform through its AIM-listing and subsequent
multiple partnering deals. I believe the team's world-class
scientific expertise, tenacity, and dedication, combined with
proprietary cutting-edge technologies provide a truly
ground-breaking capability that can efficiently deliver
world-leading medicines that can meaningfully impact the lives of
patients. I wish the team well as I move on to my next role and
look forward to hearing about their next achievements."
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFVLLFFFLXFBV
(END) Dow Jones Newswires
November 19, 2021 02:00 ET (07:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Mar 2024 to Apr 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2023 to Apr 2024